DeepMed Research

BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: BAY2965501
Drug: Platinum-based Chemotherapy
Drug: Pembrolizumab

First Posted Date: 2022-11-14

Last Posted Date: 2025-04-30

Lead Sponsor: Bayer

Target Recruit Count: 284

Registration Number: NCT05614102

Locations: 🇬🇧
Oxford University Hospitals NHS Foundation Trust | Churchill Hospital - Oncology, Oxford, Oxfordshire, United Kingdom
🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

and more 18 locations

A Study to Learn How the Study Treatment BAY1753011 Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body When Given Once as Tablet in Male and Female Participants With Reduced Kidney Function Compared to Matched Participants With Normal Kidney Function

Phase 1

Completed

Conditions: Congestive Heart Failure
Renal Impairment

Interventions: Drug: Pecavaptan (BAY1753011)

First Posted Date: 2022-10-31

Last Posted Date: 2022-10-31

Lead Sponsor: Bayer

Target Recruit Count: 32

Registration Number: NCT05599997

Locations: 🇩🇪
APEX GmbH, München, Bayern, Germany
🇩🇪
CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany

An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib

Completed

Conditions: SARS-CoV-2 Infection
Coronavirus Disease 2019 (COVID-19)
Malignant Solid Tumors

Interventions: Drug: Other TKIs
Drug: Non-TKIs
Drug: Regorafenib (Stivarga, BAY73- 4506)
Drug: Sorafenib (Nexavar, BAY43-9006)

First Posted Date: 2022-10-26

Last Posted Date: 2023-11-07

Lead Sponsor: Bayer

Target Recruit Count: 4103

Registration Number: NCT05594147

Locations: 🇺🇸
Bayer, Whippany, New Jersey, United States

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

Phase 3

Active, not recruiting

Conditions: Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
Hot Flashes

Interventions: Drug: Elinzanetant (BAY3427080)
Drug: Placebo

First Posted Date: 2022-10-20

Last Posted Date: 2025-04-15

Lead Sponsor: Bayer

Target Recruit Count: 473

Registration Number: NCT05587296

Locations: 🇫🇷
Institut Bergonie - Unicancer Nouvelle Aquitaine, Bordeaux Cedex, France
🇫🇷
Institut de Cancerologie Ouest - Saint-Herblain - Service gynecologie medicale, Saint-Herblain, France
🇮🇱
Meir Medical Center, Kfar Saba, Israel

and more 99 locations

A Study to Learn How Safe the Study Treatment BAY2395840 is, How it Affects the Body and How it Moves Into, Through, and Out of the Body if Given in Single and in Repetitive Doses to Japanese Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Volunteers
Diabetic Neuropathic Pain

Interventions: Drug: BAY2395840

First Posted Date: 2022-10-03

Last Posted Date: 2023-03-15

Lead Sponsor: Bayer

Target Recruit Count: 24

Registration Number: NCT05563454

Locations: 🇯🇵
SOUSEIKAI Fukuoka Mirai Hospital, Fukuoka, Japan

A Study Called SMART-Finder to Look for People With Increased Amounts of Albumin in the Urine (UACR Level) in a Group of Type 2 Diabetes Mellitus Patients

Recruiting

Conditions: Type 2 Diabetes Mellitus
Chronic Kidney Disease

Interventions: Drug: Finerenone (Kerendia, BAY94-8862)
Drug: Type 2 DM drugs

First Posted Date: 2022-09-23

Last Posted Date: 2025-05-13

Lead Sponsor: Bayer

Target Recruit Count: 5000

Registration Number: NCT05552339

Locations: 🇩🇪
Many locations, Multiple Locations, Germany

An Observational Study, Called RegoFlex EU, to Learn More About the Use of Stivarga at Reduced Doses as Recommended (Flexible Dosing) to Treat People With Metastatic Colorectal Cancer in Real World Settings in Europe

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Other: Retrospective patient chart review

First Posted Date: 2022-09-22

Last Posted Date: 2023-01-26

Lead Sponsor: Bayer

Target Recruit Count: 300

Registration Number: NCT05551039

Locations: 🇺🇸
Many locations, Whippany, New Jersey, United States

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: BAY3375968
Drug: Pembrolizumab

First Posted Date: 2022-09-13

Last Posted Date: 2025-04-24

Lead Sponsor: Bayer

Target Recruit Count: 354

Registration Number: NCT05537740

Locations: 🇧🇪
Ghent University Hospital | Drug Research Unit Department, Gent, Belgium
🇫🇷
Institut de Cancerologie Ouest - Saint Herblain - Oncologie medicale, Saint Herblain, France
🇫🇷
Institut Gustave Roussy - Departement d'Innovation Therapeutique et d'Essais Precoces (DITEP), Villejuif Cedex, France

and more 26 locations

A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT)

Phase 1

Terminated

Conditions: Chronic Heart Failure

Interventions: Drug: BAY2413555 Dose 1
Drug: Placebo to BAY2413555
Drug: BAY2413555 Dose 2

First Posted Date: 2022-09-08

Last Posted Date: 2024-03-12

Lead Sponsor: Bayer

Target Recruit Count: 22

Registration Number: NCT05532046

Locations: 🇮🇹
Humanitas Research Hospital | Cardio Center - Clinical, Interventional Cardiology and Coronary Care, Milano, Lombardia, Italy
🇺🇸
Accel Research Sites - Atlanta Clinical Research Center, Atlanta, Georgia, United States
🇺🇸
White Oak Medical Center, Silver Spring, Maryland, United States

and more 15 locations

A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide

Phase 2

Completed

Conditions: Biochemically Recurrent Prostate Cancer

Interventions: Drug: Darolutamide(BAY1841788, Nubeqa)
Drug: Enzalutamide

First Posted Date: 2022-09-02

Last Posted Date: 2025-05-02

Lead Sponsor: Bayer

Target Recruit Count: 65

Registration Number: NCT05526248

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center New York - Main Campus, New York, New York, United States
🇺🇸
Unio Specialty Care - Urology - Sherman Oaks, Sherman Oaks, California, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy